Cisplatin, bleomycin, and vinblastine combination therapy of testicular tumors

an analysis.

J. C. D'Aoust, A. W. Prestayko, Lawrence Einhorn, R. L. Comis, S. J. Ginsberg, W. A. Archambault, S. T. Crooke

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A combination regimen consisting of cisplatin, bleomycin, and vinblastine was evaluated in 86 patients with metastatic testicular tumors. Prior therapy included surgical resection of primary tumor (84 patients), radiotheapy (21 patients), chemotherapy (33 patients). Thirteen patients received prior bleomycin and vincristine or vinblastine. Of 80 evaluable patients 51 achieved complete response (CR) and 26 achieved partial response (PR), for an overall response rate 96.5%. There was no significant difference in response rates or survival with respect to prior therapy, sites of metastatic lesions, and tumor histology. The median survival time was not reached in an observation period of 44+ months. Sixty patients were alive 11+--44+ months, and 57 of these were free of disease. Thirty-two of the 60 patients (53%) had a survival time greater than 20 months. Toxicities included nephrotoxicity (18 patients) leukopenia, (69 patients), thrombocytopenia (nine patients), and anemia (56 patients). Bleomycin-induced pulmonary toxicity was fatal in one patient. Other toxicities included nausea and vomiting, stomatitis, fever, alopecia, and neurological effects.

Original languageEnglish
Pages (from-to)195-205
Number of pages11
JournalMedical and Pediatric Oncology
Volume6
Issue number3
StatePublished - 1979

Fingerprint

Vinblastine
Bleomycin
Testicular Neoplasms
Cisplatin
Therapeutics
Stomatitis
Survival
Alopecia
Leukopenia
Vincristine
Thrombocytopenia
Nausea
Vomiting
Anemia
Neoplasms
Histology
Fever
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

D'Aoust, J. C., Prestayko, A. W., Einhorn, L., Comis, R. L., Ginsberg, S. J., Archambault, W. A., & Crooke, S. T. (1979). Cisplatin, bleomycin, and vinblastine combination therapy of testicular tumors: an analysis. Medical and Pediatric Oncology, 6(3), 195-205.

Cisplatin, bleomycin, and vinblastine combination therapy of testicular tumors : an analysis. / D'Aoust, J. C.; Prestayko, A. W.; Einhorn, Lawrence; Comis, R. L.; Ginsberg, S. J.; Archambault, W. A.; Crooke, S. T.

In: Medical and Pediatric Oncology, Vol. 6, No. 3, 1979, p. 195-205.

Research output: Contribution to journalArticle

D'Aoust, JC, Prestayko, AW, Einhorn, L, Comis, RL, Ginsberg, SJ, Archambault, WA & Crooke, ST 1979, 'Cisplatin, bleomycin, and vinblastine combination therapy of testicular tumors: an analysis.', Medical and Pediatric Oncology, vol. 6, no. 3, pp. 195-205.
D'Aoust JC, Prestayko AW, Einhorn L, Comis RL, Ginsberg SJ, Archambault WA et al. Cisplatin, bleomycin, and vinblastine combination therapy of testicular tumors: an analysis. Medical and Pediatric Oncology. 1979;6(3):195-205.
D'Aoust, J. C. ; Prestayko, A. W. ; Einhorn, Lawrence ; Comis, R. L. ; Ginsberg, S. J. ; Archambault, W. A. ; Crooke, S. T. / Cisplatin, bleomycin, and vinblastine combination therapy of testicular tumors : an analysis. In: Medical and Pediatric Oncology. 1979 ; Vol. 6, No. 3. pp. 195-205.
@article{810247a9cee449d5b714f451b34431de,
title = "Cisplatin, bleomycin, and vinblastine combination therapy of testicular tumors: an analysis.",
abstract = "A combination regimen consisting of cisplatin, bleomycin, and vinblastine was evaluated in 86 patients with metastatic testicular tumors. Prior therapy included surgical resection of primary tumor (84 patients), radiotheapy (21 patients), chemotherapy (33 patients). Thirteen patients received prior bleomycin and vincristine or vinblastine. Of 80 evaluable patients 51 achieved complete response (CR) and 26 achieved partial response (PR), for an overall response rate 96.5{\%}. There was no significant difference in response rates or survival with respect to prior therapy, sites of metastatic lesions, and tumor histology. The median survival time was not reached in an observation period of 44+ months. Sixty patients were alive 11+--44+ months, and 57 of these were free of disease. Thirty-two of the 60 patients (53{\%}) had a survival time greater than 20 months. Toxicities included nephrotoxicity (18 patients) leukopenia, (69 patients), thrombocytopenia (nine patients), and anemia (56 patients). Bleomycin-induced pulmonary toxicity was fatal in one patient. Other toxicities included nausea and vomiting, stomatitis, fever, alopecia, and neurological effects.",
author = "D'Aoust, {J. C.} and Prestayko, {A. W.} and Lawrence Einhorn and Comis, {R. L.} and Ginsberg, {S. J.} and Archambault, {W. A.} and Crooke, {S. T.}",
year = "1979",
language = "English",
volume = "6",
pages = "195--205",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Cisplatin, bleomycin, and vinblastine combination therapy of testicular tumors

T2 - an analysis.

AU - D'Aoust, J. C.

AU - Prestayko, A. W.

AU - Einhorn, Lawrence

AU - Comis, R. L.

AU - Ginsberg, S. J.

AU - Archambault, W. A.

AU - Crooke, S. T.

PY - 1979

Y1 - 1979

N2 - A combination regimen consisting of cisplatin, bleomycin, and vinblastine was evaluated in 86 patients with metastatic testicular tumors. Prior therapy included surgical resection of primary tumor (84 patients), radiotheapy (21 patients), chemotherapy (33 patients). Thirteen patients received prior bleomycin and vincristine or vinblastine. Of 80 evaluable patients 51 achieved complete response (CR) and 26 achieved partial response (PR), for an overall response rate 96.5%. There was no significant difference in response rates or survival with respect to prior therapy, sites of metastatic lesions, and tumor histology. The median survival time was not reached in an observation period of 44+ months. Sixty patients were alive 11+--44+ months, and 57 of these were free of disease. Thirty-two of the 60 patients (53%) had a survival time greater than 20 months. Toxicities included nephrotoxicity (18 patients) leukopenia, (69 patients), thrombocytopenia (nine patients), and anemia (56 patients). Bleomycin-induced pulmonary toxicity was fatal in one patient. Other toxicities included nausea and vomiting, stomatitis, fever, alopecia, and neurological effects.

AB - A combination regimen consisting of cisplatin, bleomycin, and vinblastine was evaluated in 86 patients with metastatic testicular tumors. Prior therapy included surgical resection of primary tumor (84 patients), radiotheapy (21 patients), chemotherapy (33 patients). Thirteen patients received prior bleomycin and vincristine or vinblastine. Of 80 evaluable patients 51 achieved complete response (CR) and 26 achieved partial response (PR), for an overall response rate 96.5%. There was no significant difference in response rates or survival with respect to prior therapy, sites of metastatic lesions, and tumor histology. The median survival time was not reached in an observation period of 44+ months. Sixty patients were alive 11+--44+ months, and 57 of these were free of disease. Thirty-two of the 60 patients (53%) had a survival time greater than 20 months. Toxicities included nephrotoxicity (18 patients) leukopenia, (69 patients), thrombocytopenia (nine patients), and anemia (56 patients). Bleomycin-induced pulmonary toxicity was fatal in one patient. Other toxicities included nausea and vomiting, stomatitis, fever, alopecia, and neurological effects.

UR - http://www.scopus.com/inward/record.url?scp=0018337342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018337342&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 195

EP - 205

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -